TON - March 2018, Vol 11, No 1
According to the review of approximately 300,000 patients by Sikander Ailawadhi, MD, Oncologist, Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, and colleagues, there was also significant heterogeneity in practice patterns across all characteristics studied.
An interrupted time-series analysis by David Merola, PharmD candidate, Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, and colleagues, showed a significant increase in missed workdays per month after the initial diagnosis of multiple myeloma among patients who received oral or injectable cancer therapy.
Treatment with ivosidenib, an IDH1 inhibitor, resulted in an objective response rate of 41.6% in a phase 1 dose-escalation and expansion clinical trial of patients with relapsed or refractory acute myeloid leukemia and IDH1 mutation, according to data presented at ASH 2017.
AONN+ is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. This particular meeting was all about metrics.
For the first time, a randomized clinical trial has shown significant tumor shrinkage with a phosphoinositide-3-kinase inhibitor in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results presented at the 2017 ESMO Congress.
“There’s a human behind the patient, and he can tell us what he needs. He’s really the expert in the field,” Christine B. Boers-Doets, MSc, Netherlands Leiden University Medical Center, told attendees at the recent ESMO International Consensus Conference for Advanced Breast Cancer.
Similar to other disease sites, prostate cancer has seen a surge in genetic testing options. To help address the role of genetic testing in prostate cancer disease management, the NCCN Clinical Practice Guidelines in Oncology were updated in February 2018 to include germline recommendations.
Advocacy usually begins with personal crisis and the need for support, but it eventually moves on to sharing experiences and information with others, speaking out in public forums, and working to influence change, suggested Musa Mayer, breast cancer survivor and advocate, at the recent ESMO International Consensus Conference for Advanced Breast Cancer in Lisbon, Portugal.
Results 1 - 10 of 17